CHICAGO, IL, Sibel Health, an award-winning digital health company, today announced the close of a Series C extension financing round, bringing its total Series C funding to $39 million.
The extension included several strategic investors - Maruho Co., Ltd., and Samsung Next - and builds on the company's initial Series C round, which closed earlier this year led by The Steele Foundation for Hope with significant participation from Dräger.
Sibel Health is an award-winning digital health company with a mission to deliver Better Health Data for All®. Based in Chicago with an international office in Seoul, the company's FDA-cleared ANNE® platform includes advanced wearable sensors, AI-enabled data analytics, and an integrated mobile software and cloud platform. The company's Discovery platform is used by the world's leading pharmaceutical companies for continuous data collection in the home setting for clinical trials.
(c) by Massinvestor, Inc. For contact info, please check out our
about page.
